inozyme
pharma
appoints
yves
sabbagh
senior
vice
president
chief
scientific
officer
sabbagh
brings
years
experience
rare
genetic
disorders
mineral
metabolism
research
development
programs
company
announces
retirement
david
thompson
company
open
new
laboratory
space
increase
r
capabilities
boston
globe
newswire
inozyme
pharma
nasdaq
inzy
rare
disease
biopharmaceutical
company
developing
novel
therapeutics
treatment
diseases
abnormal
mineralization
impacting
vasculature
soft
tissue
skeleton
today
announced
appointment
yves
sabbagh
senior
vice
president
chief
scientific
officer
retirement
david
thompson
inozyme
former
chief
scientific
officer
sabbagh
brings
inozyme
years
experience
rare
genetic
disorders
mineral
metabolism
responsibilities
leading
identification
evaluation
novel
therapeutic
approaches
translating
clinical
candidates
sabbagh
responsible
expanding
inozyme
proprietary
pipeline
identifying
developing
new
therapeutics
monogenic
diseases
abnormal
mineralization
yves
accomplished
scientist
areas
renal
bone
mineral
research
brings
inozyme
extensive
management
experience
leading
teams
developing
highly
innovative
drug
candidates
said
axel
bolte
msc
mba
president
chief
executive
officer
inozyme
pharma
want
express
deep
appreciation
david
extensive
contributions
last
several
years
instrumental
establishing
research
group
inozyme
portfolio
indications
look
forward
maintaining
active
relationship
david
new
role
senior
advisor
company
wish
best
prior
joining
inozyme
sabbagh
served
head
rare
renal
musculoskeletal
diseases
research
sanofi
prior
executive
role
held
scientific
roles
increasing
responsibility
sanofi
genzyme
corporation
spanning
endocrine
renal
rare
bone
diseases
including
driving
strategy
bone
indications
prior
corporate
experience
instructor
harvard
medical
school
endocrine
unit
based
compelling
science
quality
translational
research
conducted
mineralization
disorders
initial
focus
deficiencies
inozyme
potential
help
patients
devastating
debilitating
rare
diseases
currently
lack
effective
treatment
options
said
sabbagh
excited
joining
inozyme
important
time
growth
trajectory
look
forward
leveraging
company
new
lab
infrastructure
boston
innovative
seaport
district
contribute
inozyme
continued
success
bring
transformative
therapies
sabbagh
publications
book
chapters
member
several
scientific
societies
sabbagh
received
biochemistry
mcgill
university
msc
microbiology
universit√©
laval
biology
mcgill
university
conjunction
sabbagh
appointment
thompson
announced
retirement
senior
vice
president
chief
scientific
officer
thompson
step
role
following
transition
period
remain
associated
company
role
senior
advisor
inozyme
pharma
inozyme
pharma
rare
disease
biopharmaceutical
company
developing
novel
therapeutics
treatment
diseases
abnormal
mineralization
impacting
vasculature
soft
tissue
skeleton
understanding
biological
pathways
involved
mineralization
pursuing
development
potentially
therapeutics
address
underlying
causes
debilitating
diseases
well
established
two
genes
play
key
roles
critical
mineralization
pathway
defects
genes
lead
abnormal
mineralization
initially
focused
developing
novel
therapy
treat
rare
genetic
diseases
deficiencies
inozyme
pharma
founded
joseph
schlessinger
demetrios
braddock
axel
bolte
msc
mba
technology
developed
braddock
licensed
yale
university
information
please
visit
cautionary
note
regarding
statements
statements
press
release
future
expectations
plans
prospects
well
statements
regarding
matters
historical
facts
may
constitute
statements
within
meaning
private
securities
litigation
reform
act
statements
include
limited
statements
relating
research
development
programs
words
anticipate
believe
continue
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
based
management
current
expectations
future
events
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
set
forth
implied
statements
risks
uncertainties
include
limited
risks
associated
company
ability
successfully
resolve
clinical
hold
regard
planned
phase
clinical
trial
deficiency
obtain
maintain
necessary
approvals
fda
regulatory
authorities
continue
advance
product
candidates
preclinical
studies
clinical
trials
replicate
later
clinical
trials
positive
results
found
preclinical
studies
clinical
trials
product
candidates
advance
development
product
candidates
timelines
anticipates
planned
future
clinical
trials
obtain
maintain
protect
intellectual
property
rights
related
product
candidates
manage
expenses
raise
substantial
additional
capital
needed
achieve
business
objectives
discussion
risks
uncertainties
important
factors
could
cause
company
actual
results
differ
contained
statements
see
risk
factors
section
well
discussions
potential
risks
uncertainties
important
factors
company
recent
filings
securities
exchange
commission
addition
statements
included
press
release
represent
company
views
date
hereof
relied
upon
representing
company
views
date
subsequent
date
hereof
company
anticipates
subsequent
events
developments
cause
company
views
change
however
company
may
elect
update
statements
point
future
company
specifically
disclaims
obligation
investors
brian
luque
director
investor
relations
ir
media
alex
van
rees
smithsolve
ext
